Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biome Australia Ltd ( (AU:BIO) ) has shared an update.
Biome Australia Limited announced the results of its Annual General Meeting, where all resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of director Mr. Geoffrey Sam, ratification of prior issue of shares to advisors, approval of proposed issue of loan-funded shares to Geoffrey Sam, and approval of additional 10% placement capacity. These results reflect strong shareholder support and are likely to positively impact the company’s governance and strategic initiatives.
The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Limited develops, licenses, commercializes, and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines supported by clinical research. The company aims to improve health outcomes and quality of life by making products accessible through professional health channels. Incorporated in Australia in 2018, Biome distributes locally and internationally, partnering with leading microbiome research organizations to produce unique live biotherapeutic products with innovative delivery technologies.
Average Trading Volume: 269,111
Technical Sentiment Signal: Sell
Current Market Cap: A$86.04M
For a thorough assessment of BIO stock, go to TipRanks’ Stock Analysis page.